{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T12:45:09Z","timestamp":1780922709617,"version":"3.54.1"},"reference-count":29,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,10]]},"abstract":"<jats:sec>\n            <jats:title>Purpose:<\/jats:title>\n            <jats:p>To investigate the development and progression patterns of macular neovascularization (MNV)\u2013related atrophies in eyes with pathologic myopia.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>Twenty-seven eyes of 26 patients with MNV followed from its onset to progression to macular atrophy were studied. A longitudinal series of autofluorescence and optical coherence tomography images were examined for the patterns of MNV-related atrophy. Changes in best-corrected visual acuity were determined for each pattern.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>The mean age was 67.2 \u00b1 8.7 years. The mean axial length was 29.6 \u00b1 1.5 mm. Three patterns of atrophy were identified: multiple-atrophic pattern, 63% of the eyes had small atrophies occurring at multiple sites around the MNV edge; single-atrophic pattern, 18.5% had atrophies occurring only on one side of the MNV edge; and exudation-related pattern, 18.5% had atrophy occurring within a previous serous exudation or hemorrhagic area and slightly away from the MNV edge. Eyes with atrophies in multiple-atrophic and exudation-related patterns progressed to large macular atrophies involving the central fovea and showed decrease in best-corrected visual acuity during the 3-year follow-up period. Eyes with single-atrophic pattern had a sparing of the fovea and had good recovery of the best-corrected visual acuity.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>There are three patterns of MNV-related atrophy in eyes with pathologic myopia with different courses of progression.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/iae.0000000000003863","type":"journal-article","created":{"date-parts":[[2023,6,23]],"date-time":"2023-06-23T21:10:30Z","timestamp":1687554630000},"page":"1662-1672","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["MORPHOLOGIC CHARACTERISTICS AND PROGRESSION PATTERNS OF MACULAR NEOVASCULARIZATION\u2013RELATED ATROPHY IN EYES WITH PATHOLOGIC MYOPIA"],"prefix":"10.1097","volume":"43","author":[{"given":"Shiqi","family":"Xie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongshuang","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changyu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianping","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yining","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kengo","family":"Uramoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koju","family":"Kamoi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuka","family":"Onishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyoko","family":"Ohno-Matsui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20250605","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1016\/S0161-6420(03)00461-5","article-title":"Myopic choroidal neovascularization: a 10-year follow-up","volume":"110","author":"Yoshida","year":"2003","journal-title":"Ophthalmology"},{"key":"R2-20250605","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.preteyeres.2017.10.005","article-title":"Diagnosis and treatment guideline for myopic choroidal neovascularization due to pathologic myopia","volume":"63","author":"Ohno-Matsui","year":"2018","journal-title":"Prog Retin Eye Res"},{"key":"R3-20250605","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ajo.2013.08.010","article-title":"Epidemiology and disease burden of pathologic myopia and myopic choroidal neovascularization: an evidence-based systematic review","volume":"157","author":"Wong","year":"2014","journal-title":"Am J Ophthalmol"},{"key":"R4-20250605","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.ophtha.2013.10.023","article-title":"RADIANCE: a randomized controlled study of ranibizumab in patients with choroidal neovascularization secondary to pathologic myopia","volume":"121","author":"Wolf","year":"2014","journal-title":"Ophthalmology"},{"key":"R5-20250605","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1016\/j.ophtha.2015.01.025","article-title":"Intravitreal aflibercept injection in patients with myopic choroidal neovascularization: the MYRROR study","volume":"122","author":"Ikuno","year":"2015","journal-title":"Ophthalmology"},{"key":"R6-20250605","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1097\/IAE.0000000000002292","article-title":"Ranibizumab versus verteporfin photodynamic therapy in Asian patients with myopic choroidal neovascularization: BRILLIANCE, a 12-month, randomized, double-masked study","volume":"39","author":"Chen","year":"2019","journal-title":"Retina"},{"key":"R7-20250605","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00417-012-2022-8","article-title":"Long-term effect of intravitreal injection of anti-VEGF agent for visual acuity and chorioretinal atrophy progression in myopic choroidal neovascularization","volume":"251","author":"Oishi","year":"2013","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R8-20250605","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1097\/IAE.0000000000001313","article-title":"Six-year outcomes of intravitreal bevacizumab for choroidal neovascularization in patients with pathologic myopia","volume":"37","author":"Kasahara","year":"2017","journal-title":"Retina"},{"key":"R9-20250605","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1097\/IAE.0000000000000632","article-title":"Intravitreal anti-vascular endothelial growth factor therapy for choroidal neovascularization secondary to pathologic myopia: six years outcome","volume":"35","author":"Ruiz-Moreno","year":"2015","journal-title":"Retina"},{"key":"R10-20250605","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/s00417-015-3076-1","article-title":"Intravitreal bevacizumab for choroidal neovascularization due to pathologic myopia: long-term outcomes","volume":"254","author":"Sarao","year":"2016","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R11-20250605","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1097\/IAE.0b013e3182278bae","article-title":"Two-year outcomes of intravitreal bevacizumab for choroidal neovascularization in Japanese patients with pathologic myopia","volume":"32","author":"Hayashi","year":"2012","journal-title":"Retina"},{"key":"R12-20250605","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1016\/j.ophtha.2017.04.028","article-title":"Myopic choroidal neovascularization: review, guidance, and consensus statement on management","volume":"124","author":"Cheung","year":"2017","journal-title":"Ophthalmology"},{"key":"R13-20250605","doi-asserted-by":"crossref","first-page":"e0273613","DOI":"10.1371\/journal.pone.0273613","article-title":"Risk factors for myopic choroidal neovascularization-related macular atrophy after anti-VEGF treatment","volume":"17","author":"Bae","year":"2022","journal-title":"PLoS One"},{"key":"R14-20250605","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.preteyeres.2015.12.001","article-title":"Updates of pathologic myopia","volume":"52","author":"Ohno-Matsui","year":"2016","journal-title":"Prog Retin Eye Res"},{"key":"R15-20250605","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.ajo.2009.03.026","article-title":"Comparison of visual outcome and regression pattern of myopic choroidal neovascularization after intravitreal bevacizumab or after photodynamic therapy","volume":"148","author":"Hayashi","year":"2009","journal-title":"Am J Ophthalmol"},{"key":"R16-20250605","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1007\/s00417-011-1921-4","article-title":"Factors associated with enlargement of chorioretinal atrophy after intravitreal bevacizumab for myopic choroidal neovascularization","volume":"250","author":"Uemoto","year":"2012","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R17-20250605","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.ajo.2015.11.014","article-title":"Macular Bruch membrane holes in choroidal neovascularization-related myopic macular atrophy by swept-source optical coherence tomography","volume":"162","author":"Ohno-Matsui","year":"2016","journal-title":"Am J Ophthalmol"},{"key":"R18-20250605","doi-asserted-by":"crossref","first-page":"2679","DOI":"10.1007\/s00417-021-05142-y","article-title":"Choroidal neovascularization secondary to pathological myopia-macular Bruch membrane defects as prognostic factor to anti-VEGF treatment","volume":"259","author":"Coelho","year":"2021","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R19-20250605","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1097\/IAE.0000000000002575","article-title":"Clinical features of patchy chorioretinal atrophy in pathologic myopia","volume":"40","author":"Du","year":"2020","journal-title":"Retina"},{"key":"R20-20250605","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s00417-004-0960-5","article-title":"Characteristics of patients with a favorable natural course of myopic choroidal neovascularization","volume":"243","author":"Hayashi","year":"2005","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R21-20250605","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1023\/A:1025488429802","article-title":"The natural history of juxtafoveal and subfoveal choroidal neovascularization in high myopia","volume":"24","author":"Bottoni","year":"2001","journal-title":"Int Ophthalmol"},{"key":"R22-20250605","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1038\/eye.2010.226","article-title":"Prognostic factors for visual outcomes 2-years after intravitreal bevacizumab for myopic choroidal neovascularization","volume":"25","author":"Nakanishi","year":"2011","journal-title":"Eye"},{"key":"R23-20250605","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/0002-9394(82)90301-4","article-title":"Experimental subretinal hemorrhage in rabbits","volume":"94","author":"Glatt","year":"1982","journal-title":"Am J Ophthalmol"},{"key":"R24-20250605","first-page":"1068","article-title":"Absorption of retinal and subretinal hemorrhages","volume":"15","author":"Gillies","year":"1983","journal-title":"Ann Ophthalmol"},{"key":"R25-20250605","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/S0039-6257(97)00089-1","article-title":"Pathophysiology and management of subretinal hemorrhage","volume":"42","author":"Hochman","year":"1997","journal-title":"Surv Ophthalmol"},{"key":"R26-20250605","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1016\/j.ophtha.2009.11.003","article-title":"Long-term pattern of progression of myopic maculopathy: a natural history study","volume":"117","author":"Hayashi","year":"2010","journal-title":"Ophthalmology"},{"key":"R27-20250605","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.ophtha.2017.12.005","article-title":"Progression of myopic maculopathy during 18-year follow-up","volume":"125","author":"Fang","year":"2018","journal-title":"Ophthalmology"},{"key":"R28-20250605","doi-asserted-by":"crossref","first-page":"6358","DOI":"10.1167\/iovs.17-22633","article-title":"Patchy chorioretinal atrophy changes at the posterior Pole after ranibizumab for myopic choroidal neovascularization","volume":"58","author":"Parravano","year":"2017","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R29-20250605","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1007\/s00417-018-04214-w","article-title":"Effect of intravitreal injection of aflibercept or ranibizumab on chorioretinal atrophy in myopic choroidal neovascularization","volume":"257","author":"Sayanagi","year":"2019","journal-title":"Graefes Arch Clin Exp Ophthalmol"}],"container-title":["Retina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/IAE.0000000000003863","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T17:04:13Z","timestamp":1749143053000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/IAE.0000000000003863"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":29,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/iae.0000000000003863","relation":{},"ISSN":["0275-004X"],"issn-type":[{"value":"0275-004X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]}}}